Akiyuki Uzawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2037008/publications.pdf

Version: 2024-02-01

		201674	206112
111	2,843	27	48
papers	citations	h-index	g-index

115	115	115	2652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
2	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis Journal, 2010, 16, 1443-1452.	3.0	285
3	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
4	Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. Journal of Neurology, 2009, 256, 2082-2084.	3.6	104
5	Different responses to interferon betaâ€1b treatment in patients with neuromyelitis optica and multiple sclerosis. European Journal of Neurology, 2010, 17, 672-676.	3.3	89
6	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. Brain Pathology, 2014, 24, 67-73.	4.1	79
7	Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica Chimica Acta, 2013, 421, 181-183.	1.1	74
8	Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clinical and Experimental Immunology, 2014, 176, 232-237.	2.6	64
9	Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clinical and Experimental Immunology, 2021, 203, 366-374.	2.6	57
10	Neuromyelitis optica: Concept, immunology and treatment. Journal of Clinical Neuroscience, 2014, 21, 12-21.	1.5	48
11	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on bloodâ€“brain barrier disruption. Multiple Sclerosis Journal, 2017, 23, 1072-1084.	3.0	48
12	CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 517-522.	1.9	44
13	Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2013, 172, 37-43.	2.6	44
14	Early fastâ€acting treatment strategy against generalized myasthenia gravis. Muscle and Nerve, 2017, 55, 794-801.	2.2	44
15	Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. Journal of the Neurological Sciences, 2009, 287, 105-107.	0.6	43
16	CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 339-340.	1.9	41
17	Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica. Archives of Neurology, 2011, 68, 913.	4.5	40
18	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38

#	Article	IF	Citations
19	Changes in inflammatory cytokine networks in myasthenia gravis. Scientific Reports, 2016, 6, 25886.	3.3	37
20	Soluble CD40 ligand contributes to bloodâ€“brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2017, 305, 102-107.	2.3	35
21	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642090420.	3.5	34
22	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clinica Chimica Acta, 2017, 469, 144-149.	1.1	32
23	Epstein-Barr virus persistence and reactivation in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1137-1142.	1.9	31
24	Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurology, 2010, 10, 113.	1.8	30
25	Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. European Journal of Neurology, 2016, 23, 276-281.	3.3	30
26	Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes. JAMA Neurology, 2021, 78, 853.	9.0	30
27	Adequate tacrolimus concentration for myasthenia gravis treatment. European Journal of Neurology, 2017, 24, 270-275.	3.3	29
28	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	2.3	28
29	A clinical predictive score for postoperative myasthenic crisis. Annals of Neurology, 2017, 82, 841-849.	5.3	27
30	Current symptomatology in multiple sclerosis and neuromyelitis optica. European Journal of Neurology, 2015, 22, 299-304.	3.3	25
31	Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. Journal of Neurology, 2015, 262, 1019-1023.	3.6	23
32	Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurology, 2016, 16, 225.	1.8	22
33	Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. Journal of the Neurological Sciences, 2019, 396, 8-11.	0.6	22
34	Serum high mobility group box 1 is upregulated in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 695-697.	1.9	21
35	HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. Journal of the Neurological Sciences, 2016, 363, 116-118.	0.6	21
36	Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. Journal of the Neurological Sciences, 2019, 402, 12-15.	0.6	21

#	Article	IF	Citations
37	Anti-N-methyl d-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clinical Neurology and Neurosurgery, 2012, 114, 402-404.	1.4	20
38	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	2.3	20
39	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 132-139.	1.9	20
40	Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 513-517.	1.9	19
41	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.6	18
42	Anti-MOG antibodyâ€“associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	1.9	18
43	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. Journal of the Neurological Sciences, 2016, 367, 375-379.	0.6	16
44	Serum antiâ€ŁRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16
45	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. Journal of Neurology, 2018, 265, 1145-1150.	3.6	15
46	Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1189-1194.	1.9	15
47	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 32-40.	1.9	15
48	Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2014, 178, 245-252.	2.6	14
49	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 147-149.	0.6	14
50	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731875969.	1.0	14
51	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clinical and Experimental Immunology, 2018, 193, 47-54.	2.6	14
52	Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 963-968.	1.9	14
53	Isolated abducens and facial nerve palsies due to a facial collicular plaque in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 85-86.	1.9	13
54	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5.5	13

#	Article	IF	Citations
55	When is neuromyelitis optica diagnosed after disease onset?. Journal of Neurology, 2012, 259, 1600-1605.	3.6	11
56	Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan. Multiple Sclerosis Journal, 2013, 19, 378-379.	3.0	11
57	Increased serum peroxiredoxin 5 levels in myasthenia gravis. Journal of Neuroimmunology, 2015, 287, 16-18.	2.3	11
58	Soluble CD40 ligand disrupts the bloodâ€“brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2018, 316, 117-120.	2.3	11
59	Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 868.	2.4	11
60	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. PLoS ONE, 2020, 15, e0224419.	2.5	11
61	High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. Journal of Neuroimmunology, 2021, 358, 577634.	2.3	11
62	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 453, 131-133.	1.1	10
63	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. PLoS ONE, 2017, 12, e0184012.	2.5	10
64	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 385, 64-68.	0.6	10
65	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Multiple Sclerosis Journal, 2016, 22, 1371-1375.	3.0	9
66	Frequency and features of myasthenia gravis developing after thymectomy. European Journal of Neurology, 2020, 27, 175-180.	3.3	9
67	Long-term outcomes and prognostic factors in generalized myasthenia gravis. Journal of Neurology, 2021, 268, 3781-3788.	3.6	9
68	Role of interleukinâ€6 in the pathogenesis of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 167-172.	1.0	8
69	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2016, 7, 52-58.	1.0	8
70	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 78-84.	0.6	8
71	Changes in serum complements and their regulators in generalized myasthenia gravis. European Journal of Neurology, 2021, 28, 314-322.	3.3	8
72	Safety of tapering tacrolimus dose in patients with wellâ€controlled antiâ€acetylcholine receptor antibodyâ€positive myasthenia gravis. European Journal of Neurology, 2020, 27, 100-104.	3.3	7

#	Article	IF	Citations
73	Wall-Eyed Bilateral Internuclear Ophthalmoplegia by Ischemic Stroke. Neurologist, 2020, 25, 82-84.	0.7	7
74	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. Journal of Neurology, 2012, 259, 980-981.	3.6	6
75	A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells. Neurotherapeutics, 2017, 14, 191-198.	4.4	6
76	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2020, 202, 239-248.	2.6	6
77	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	1.0	6
78	Intrathymic Plasmablasts Are Affected in Patients With Myasthenia Gravis With Active Disease. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	6
79	Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 409-412.	1.0	5
80	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. Journal of Neuroimmunology, 2017, 305, 131-134.	2.3	5
81	Severe worsening of myasthenic symptoms after the eculizumab discontinuation. Journal of Neuroimmunology, 2020, 349, 577424.	2.3	5
82	Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy. Journal of Neuroimmunology, 2022, 365, 577833.	2.3	5
83	Benign neuromyelitis optica is rare in Japanese patients. Multiple Sclerosis Journal, 2015, 21, 1204-1208.	3.0	4
84	MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 900-900.	1.9	4
85	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 128-129.	3.0	4
86	Comparison of brain atrophy in patients with multiple sclerosis treated with firstâ€•versus secondâ€generation disease modifying therapy without clinical relapse. European Journal of Neurology, 2020, 27, 2056-2061.	3.3	4
87	Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19. Internal Medicine, 2022, 61, 1071-1076.	0.7	4
88	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. Internal Medicine, 2022, 61, 2785-2787.	0.7	4
89	Case of convulsive seizure developing during electroretinographic recordings: a case report. BMC Neurology, 2018, 18, 52.	1.8	3
90	Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study. Clinical and Experimental Immunology, 2020, 202, 321-324.	2.6	3

#	Article	IF	Citations
91	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 348-348.	1.9	3
92	Dispersion of mean consecutive differences in singleâ€fiber electromyography increases diagnostic sensitivity for myasthenia gravis. Muscle and Nerve, 2021, 63, 885-889.	2.2	3
93	Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine. Case Reports in Medicine, 2011, 2011, 1-3.	0.7	2
94	Cryptococcal Meningitis in a Fingolimod-Treated Patient. Neurology: Clinical Practice, 2021, 11, e549-e550.	1.6	2
95	Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders. Clinical and Experimental Neuroimmunology, 2013, 4, 206-209.	1.0	1
96	Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. Clinical and Experimental Neuroimmunology, 2015, 6, 299-303.	1.0	1
97	Spinal myoclonus selectively affecting the platysma after cervical laminectomy. Neurology, 2018, 91, 45-46.	1.1	1
98	Increased serum acetylcholine receptor Î±1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis. Journal of Neuroimmunology, 2020, 339, 577125.	2.3	1
99	Longâ€term prognosis of Japanese Lambertâ€“Eaton myasthenic syndrome patients with or without smallâ€cell lung carcinoma. Clinical and Experimental Neuroimmunology, 2020, 11, 131-134.	1.0	1
100	High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model. NeuroReport, 2021, 32, 803-807.	1.2	1
101	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. Journal of Neurology, 2021, , 1.	3.6	1
102	Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis. Scandinavian Journal of Immunology, 2021, , e13122.	2.7	1
103	Impaired neuromuscular transmission in facial muscles of amyotrophic lateral sclerosis: A singleâ€fiber electromyography study. Neurology and Clinical Neuroscience, 0, , .	0.4	1
104	Multiple enhancing brain lesions after discontinuation of fingolimod in a patient with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 52-53.	1.0	0
105	The role of granulocyteâ€macrophage colonyâ€stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. Clinical and Experimental Neuroimmunology, 2015, 6, 70-77.	1.0	0
106	Relationship between damage-associated molecular patterns and cytokines in myasthenia gravis. Clinical and Experimental Neuroimmunology, 2016, 7, 357-360.	1.0	0
107	Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 620-620.	1.9	0
108	Response to â€œLetter to the editors in regard to the article â€˜Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravisâ€™â€• Journal of the Neurological Sciences, 2019, 404, 157-158.	0.6	0

#	Article	IF	Citations
109	Response to â€œregarding the article â€˜Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravisâ€™â€• Journal of the Neurological Sciences, 2019, 399, 229.	0.6	0
110	Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis. JAMA Neurology, 2021, 78, 1153.	9.0	0
111	Delayed Appearance of Brain Magnetic Resonance Imaging Abnormalities in a Patient with Glial Fibrillary Acidic Protein Astrocytopathy. Internal Medicine, 2022, , .	0.7	0